Adlai Nortye Ltd. granted Jiangsu Aosaikang Pharmaceutical (Ask Pharm) an exclusive license for AN‑9025, a pan‑RAS(ON) oral small molecule designed to target diverse RAS mutations. The deal transfers China rights to Ask Pharm for further development and commercialization. AN‑9025 aims to address the long‑running RAS oncology opportunity by targeting multiple RAS mutants; regional licensing accelerates local clinical development and regulatory engagement in China. The collaboration reflects continued biopharma interest in expanding RAS inhibitor footprints through regional partners with established regulatory and commercialization capabilities. Financial terms were not disclosed; watch for clinical development timelines and any retained rights or milestone obligations disclosed by Adlai Nortye.